
Robotics that enables people to do what they cannot do

It all began with a question that wouldn’t leave a young engineer’s mind. In a robotics club at the École polytechnique, Nicolas Simon watched a machine learn to walk and thought of his brother, who was in the process of losing that ability. If a robot can walk, why don’t we build one that can walk for him?
Wandercraft was founded in Paris in 2012 to address this challenge—and the solution required a decade of development: a self-balancing exoskeleton so that the person wearing it doesn’t have to balance themselves. In 2019, Atalante became the first self-balancing walking exoskeleton to receive CE marking in Europe.
Today, this same technology supports people through rehabilitation at more than 150 clinical and research sites, moves from the clinic into people’s homes with Eve, and powers Calvin, our family of humanoid robots designed for the toughest industrial tasks. Three products, two markets, one conviction: Robotics should help people do what they cannot do themselves.
The same self-balancing technology across three orders of magnitude—from clinical exoskeletons to humanoid robots for the factory floor.

Our clinical exoskeleton, which allows patients in rehabilitation to walk hands-free and without a walking aid.

Our personal exoskeleton—designed to leave the hospital and go home with the person wearing it.

Our humanoid robot, designed for the toughest and most repetitive tasks on the production floor.
Fourteen years, three robots, and an idea that just wouldn't go away. Scroll to the side to follow it.
Nicolas Simon, Matthieu Masselin, and Jean-Louis Constanza founded Wandercraft in Paris—inspired by a brother and a son who lost the ability to walk.

The world's first clinical trials using our prototypes show that people with paraplegia can walk hands-free and without a walking aid.

The world's first self-balancing exoskeleton has been approved in Europe—the first patients are now using it in rehabilitation clinics.

Atalante has received FDA approval for stroke rehabilitation, opening the door to U.S. hospitals—and, in the coming year, to the expansion of our operations in the United States.

At Paris 2024, our exoskeletons will carry the Olympic and Paralympic torches—including Thibault Simon, the brother whose story started it all.

Our self-balancing personal exoskeleton is set to begin clinical trials with people living with spinal cord injuries—at the Bronx VA and at Kessler.

Renault Group is taking a stake in the company and will become our industrial partner—along with a Series D funding round to ramp up production worldwide.

Building on more than a decade of exoskeleton development, the first Calvin prototype is being built in 40 days. Calvin-40 is unveiled—with the Renault Group as its first customer.

Calvin-40 is in use on the production line at the Renault plant in Douai—a fleet of 350 robots has been ordered through 2027.

Eve will be the first self-balancing personal exoskeleton approved for home use by people with spinal cord injuries.

More than 175 world-class experts in AI, robotics, and industry—at our two headquarters in Paris and New York.


















We don't just hire people. We're building a team of pioneers, curious minds, and problem-solvers who want to change the world—one step at a time.
Apply
Our Paris office has its own walking training center; there is another one in New York City, and more are being added across the U.S. Users train here every day on-site—so there’s no need to wonder who this work is intended for.
Full-body control, embedded AI, certifiable safety, robots that carry people, and robots that carry loads—and a production line waiting for the answer.
Our internal Expert Track allows engineers to specialize in a particular field rather than advance through management roles. Seniority here is not determined solely by the number of employees.
Paris and New York, deliberately brought together: company-wide events every year and commitments to well-being that we actually put in writing.
Join us in shaping the next generation of medical and humanoid robotics—driven by AI and a clear mission.